EGFR and cancer: It was shown that small molecular degraders based on allosteric EGFR-TKI selectively inhibit the proliferation of cancer cells carrying the EGFRL858R/T790M double mutant and the osimertinib-resistant triple mutants, EGFRL858R/T790M/C797S and EGFRL858R/T790M/L718Q [64].